Shots: Abbott to launch TRILUMINATE pivotal study to evaluate TriClip transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation. In TRILUMINATE pivotal study, ~700 patients are expected […]readmore
Tags : Abbott
Shots: The TRACK-TBI study evaluated its blood test technology in 450 patients admitted to the emergency department of 18 U.S. Level 1 trauma centers with suspected TBI, who has also […]readmore
With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing […]readmore
Shots: MitraClip G4 is a fourth-generation MitraClip device offering a new option to physicians for treating leaky mitral valve in the US with an expanded range of clip sizes and […]readmore
Shots: Alinity s System is designed to screen blood and plasma efficiently within a smaller space and helps improve the productivity of blood & plasma centers by maintaining its accuracy […]readmore
Shots: Abbott’s Afinion HbA1c Dx assay is a rapid point-of-care test, available for use on the Afinion 2 Analyzer & Afinion AS100 Analyzer to aid health care professionals in the […]readmore
Shots: The TRILUMINATE study results involve assessing transcatheter tricuspid valve repair system in 85 patients with symptomatic moderate or greater tricuspid regurgitation across 21 sites including the US and Europe […]readmore
Shots: Abbott to provide its neuromodulation technologies including deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy. NIH to utilize Abbott’s technology for exploring its […]readmore
Top 20 BioPharma Companies based on 2018 Total Revenue The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics […]readmore
Shots: The Atherosclerosis Risk in Communities (ARIC) study results involves assessing of high-sensitive troponin-I blood test in 8,121 candidates with no known cardiovascular disease aged 54-73yrs. for 15yrs. The ARIC […]readmore